AustinPx, a Texas-based Contract Development and Manufacturing Organization (CDMO) specializing in bioavailability enhancement, has forged an exclusive agreement with Thermo Fisher Scientific’s Patheon division to integrate its innovative KinetiSol technology into Patheon’s global network. Announced on June 30, 2026, this landmark collaboration will see KinetiSol equipment installed at Patheon’s facilities in Bend, Oregon, and Cincinnati, Ohio, significantly expanding commercial access to AustinPx’s advanced amorphous solid dispersion (ASD) capabilities. The partnership positions Patheon as the exclusive third-party CDMO offering early-phase KinetiSol development on the Formulator scale, while AustinPx continues to provide its established KinetiSol services directly to clients. This strategic move aims to address the pervasive challenge of poor drug solubility in pharmaceutical development, offering sponsors a more robust and scalable pathway for their most challenging small molecule candidates.
The Pressing Challenge of Poor Drug Solubility
The pharmaceutical industry continually grapples with the inherent complexity of drug solubility, a critical factor directly impacting a drug’s bioavailability and, consequently, its therapeutic efficacy. According to a comprehensive 2023 review published in the journal Life, a staggering 40% of commercially available drugs and an even higher proportion, between 70% and 90%, of drug candidates currently in development exhibit poor aqueous solubility. This widespread issue presents a significant hurdle in drug formulation, as poorly soluble compounds are not readily absorbed into the bloodstream, leading to diminished therapeutic effects. To compensate, formulators often resort to higher doses, which can unfortunately exacerbate the risk of adverse side effects, impacting patient safety and compliance. The economic implications are also substantial, with extended development timelines and increased costs associated with overcoming solubility limitations. This persistent challenge underscores the critical demand for advanced bioavailability enhancement technologies that can transform poorly soluble active pharmaceutical ingredients (APIs) into effective and patient-friendly drug products.
KinetiSol: A Differentiated Approach to Bioavailability Enhancement
AustinPx’s KinetiSol technology stands as a potent solution in the landscape of bioavailability enhancement, particularly through the creation of amorphous solid dispersions (ASDs). ASDs are a widely recognized strategy where a poorly soluble drug is dispersed in an amorphous, glassy polymer matrix, thereby improving its dissolution rate and solubility. While established methods like hot-melt extrusion (HME) and spray drying (SD) have been mainstays in ASD manufacturing, KinetiSol offers a distinct advantage, particularly for APIs that present challenges to these traditional techniques.
KinetiSol operates on a principle of rapid, localized heating and mixing, using frictional energy rather than external heat sources or large volumes of solvents. This process allows for the creation of stable amorphous dispersions with minimal thermal exposure and without the need for solvents, making it highly suitable for heat-sensitive or solvent-intolerant APIs. The technology’s ability to process a wider range of polymers and excipients, including those incompatible with HME or SD, further expands its applicability. AustinPx has been at the forefront of KinetiSol development for over 16 years, accumulating extensive expertise in formulation, process development, scale-up, and technology transfer, and has served over 80 clients in this specialized field.
A Strategic Alliance: AustinPx and Patheon
The exclusive agreement between AustinPx and Thermo Fisher Scientific’s Patheon division marks a significant milestone for both companies and the broader pharmaceutical CDMO sector. Patheon, a global leader in contract development and manufacturing, provides a vast network and extensive resources, making it an ideal partner to scale KinetiSol’s reach. The installation of KinetiSol Formulator units at Patheon’s strategic sites in Bend, Oregon, and Cincinnati, Ohio, will integrate this cutting-edge technology directly into Patheon’s existing suite of advanced formulation capabilities, including its Quadrant 2 predictive platform, which leverages artificial intelligence and machine learning (AI/ML) for optimized formulation prediction.
Elizabeth Hickman, CEO of AustinPx, articulated the rationale behind this strategic partnership: "We are excited to partner with Thermo Fisher Scientific, one of the industry’s largest CMOs, to expand access to AustinPx’s KinetiSol technology. This agreement is a strong indicator of the growing demand for differentiated amorphous dispersion technologies and the need for more tools that solve increasingly complex bioavailability challenges." Hickman emphasized that while Patheon will serve as the exclusive third-party CDMO for early-phase KinetiSol development, AustinPx will continue to offer its full spectrum of KinetiSol capabilities, maintaining its role as the technology inventor, owner, and process expert. This dual-access model ensures that sponsors have multiple avenues to leverage KinetiSol, catering to different development stages and strategic needs.
Unlocking Commercial Confidence and Optionality for Sponsors
One of the most profound implications of this agreement is the enhanced commercial confidence it instills in sponsors considering KinetiSol for their drug programs. Historically, novel enabling technologies, no matter how promising, often face hesitancy from pharmaceutical companies due to concerns about their scalability and the reliability of their commercial manufacturing pathways. By partnering with a global giant like Patheon, AustinPx effectively addresses these concerns.
Hickman elaborated on this point, stating, "The agreement primarily unlocks greater confidence in the downstream path for KinetiSol-enabled products. Clients can approach KinetiSol as a scalable, commercially relevant pathway for challenging molecules from the start, instead of a specialized, last-resort option considered only after other ASD approaches are exhausted." She highlighted that KinetiSol was designed for scale, and AustinPx has already facilitated numerous technology transfers, commercial-scale equipment installations, and supported registration-scale manufacturing programs. The collaboration with Patheon adds another robust and globally recognized access point within the broader KinetiSol commercial ecosystem, which also includes AustinPx’s commercial partner, Microsize. This increased capacity and optionality are crucial for sponsors as their programs advance from early development through Phase 3 clinical trials and towards commercialization, providing assurance that KinetiSol-enabled products have a clear and de-risked path to market.
KinetiSol’s Unique Niche in Formulation Science
For formulation scientists evaluating amorphous solid dispersion routes—spray drying, hot-melt extrusion, and KinetiSol—the choice often hinges on specific API characteristics and overall product strategy. Hickman stressed that "one size does not fit all in ASD development," advocating for a holistic approach that considers performance, scale-up, manufacturability, sustainability, and long-term value.
She meticulously outlined the technical signals that point towards KinetiSol as the optimal choice:
- Poor solubility in organic solvents: This immediately rules out spray drying for many compounds.
- High melting point: Compounds with high melting points can be challenging for HME, which requires sustained thermal exposure.
- Time-dependent thermal lability or heat sensitivity: KinetiSol’s rapid, localized heating minimizes degradation risks.
- Need for specific polymers and excipients: KinetiSol offers greater flexibility in material selection, accommodating polymers and excipients not compatible with HME or SD.
- Complex, multi-component ASD systems: KinetiSol excels where simple drug-polymer approaches are insufficient.
- Pill-burden reduction: The technology can facilitate higher drug loading, leading to smaller, more patient-friendly dosage forms.
- Manufacturability improvements for cost reduction: Streamlined processes and material flexibility can lower overall manufacturing costs.
- Environmental improvements: The solvent-free nature of KinetiSol aligns with green manufacturing initiatives.
- Modified or targeted release requirements: KinetiSol’s unique processing can enable tailored drug release profiles.
By evaluating KinetiSol earlier in the development cycle, sponsors can mitigate risks, improve the odds of technical success, and potentially create more differentiated and valuable drug products.
Synergy with Predictive Formulation and AI/ML
The integration of KinetiSol with Patheon’s Quadrant 2 predictive platform represents a forward-looking approach to drug development. Quadrant 2 leverages AI/ML to predict optimal formulations, an invaluable tool, especially in the early phases when API quantities are limited and data is scarce. Hickman highlighted the significance of this synergy: "As KinetiSol is incorporated into broader predictive formulation workflows, such as Patheon’s Quadrant 2, sponsors can make better decisions, earlier, about the best formulation path forward for their molecule."
The feeding of KinetiSol process and formulation data into such AI/ML models is expected to yield substantial benefits. A larger and more diverse dataset from KinetiSol applications will refine the predictive algorithms, leading to more accurate and efficient formulation predictions over time. This doesn’t replace the nuanced expertise of formulation scientists but rather augments it, enabling teams to start from a more informed position, conserve precious API, reduce the need for low-value experiments, and proactively identify potential risks. The ultimate outcome is faster learning cycles, reduced development risk, and greater assurance that the chosen formulation strategy will support drug performance, manufacturability, and scalability. This integration underscores the industry’s shift towards data-driven drug development, where advanced technologies and computational tools work in tandem to accelerate innovation.
Shifting Paradigms: KinetiSol as a First-Choice Technology
Historically, pharmaceutical sponsors often gravitated towards spray drying and hot-melt extrusion as their default ASD technologies due to their widespread use and familiarity. This often meant KinetiSol was considered later in the development process, typically after a molecule had encountered limitations with solvent compatibility, thermal stability, formulation complexity, pill burden, or scale-up issues with conventional methods.
However, this paradigm is rapidly changing. The AustinPx-Patheon agreement serves as a powerful validation of KinetiSol’s capabilities and commercial viability, reinforcing its position as a leading-edge technology. Hickman noted, "That is changing. KinetiSol is increasingly becoming a first-choice technology for sponsors working with challenging molecules because it brings together performance, scalability, sustainability, and a broader formulation design space." The collaboration with Thermo Fisher Scientific strengthens this momentum, providing a defined and credible pathway for KinetiSol-enabled products moving towards late-stage clinical testing and commercial manufacturing. This increased confidence encourages sponsors to evaluate KinetiSol earlier in development, when formulation decisions can have the most significant impact on a drug’s success trajectory. By integrating KinetiSol into early decision-making, companies can avoid costly rework, mitigate development and scale-up risks, and ultimately create a stronger, more differentiated product with long-term market value.
Broader Industry Impact and Future Outlook
The partnership between AustinPx and Patheon is more than just a commercial agreement; it reflects broader trends within the pharmaceutical industry. It highlights the growing importance of specialized technology partnerships in an increasingly complex drug development landscape. As new chemical entities become more challenging, CDMOs are compelled to invest in or partner with innovators offering advanced solutions. This collaboration enhances the competitive offerings of both AustinPx and Patheon, positioning them at the forefront of bioavailability enhancement.
For the pharmaceutical industry at large, the expanded access to KinetiSol through Patheon signifies a collective step forward in addressing one of the most persistent hurdles in drug development. It promises to accelerate the development of new therapeutics for a wide range of diseases, potentially bringing life-changing medications to patients faster. The emphasis on commercial optionality and de-risking the development pathway for challenging molecules is a testament to the industry’s commitment to efficiency, innovation, and patient-centricity. As KinetiSol technology becomes more integrated into mainstream pharmaceutical development and manufacturing, it is poised to play a crucial role in shaping the next generation of orally delivered small molecule drugs, ensuring better bioavailability, improved patient outcomes, and sustainable manufacturing practices. This strategic alliance underscores a future where cutting-edge technology and extensive manufacturing capabilities converge to unlock the full therapeutic potential of challenging APIs.
